Washington, D.C., Jan. 24, 2025 (GLOBE NEWSWIRE) — The Thurgood Marshall College Fund (TMCF) has received a substantial grant from Lilly Endowment Inc. to…
Post-hoc analysis on survival outcomes for camrelizumab plus rivoceranib in patients with viral and non-viral hepatocellular carcinoma (HCC) demonstrated clinically…